NCT06806852 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06806852
Title	A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Boehringer Ingelheim
Indications	hypopharynx cancer oral cavity cancer oropharynx cancer laryngeal squamous cell carcinoma head and neck squamous cell carcinoma
Therapies	Pembrolizumab BI 770371 + Cetuximab + Pembrolizumab BI 770371 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| POL \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BGR \| AUS

No variant requirements are available.